Can Ozempic Slow Aging? What the New Nature Study Actually Shows (and Doesn’t)

Medically Written & Reviewed by Dr. Ajit Kumar, MD (Medicine) | MA (Psychology), Founder of Medimadad. Last reviewed: September 2026. This article is for informational purposes only and does not constitute medical advice. Read our Editorial Policy.

Key Takeaways

• A study published in Nature on September 2, 2026 found that older female mice given semaglutide (the drug in Ozempic and Wegovy) for three months lived a median of 834 days, versus 742 days for untreated mice — 92 days, or about 12%, longer.
• Separately, a UC San Diego–led analysis of a placebo-controlled human trial found semaglutide slowed several validated biological-aging clocks by roughly 9%, though the trial was run in adults with HIV-associated fat redistribution, not the general population, and wasn’t originally designed to study aging.
• Neither study proves Ozempic extends human lifespan. One is a mouse study; the other is a secondary analysis of a trial built for a different purpose.
• If you’re already taking a GLP-1 drug for weight loss or diabetes, this is genuinely encouraging supporting evidence — not a reason to start taking one purely to slow aging.

The Study Everyone’s Suddenly Talking About

Within about 48 hours of publication, the same headline was sitting in three different inboxes I check: colleagues, readers of this site, and a cousin who has never once asked me about a research paper in her life. “Does Ozempic make you live longer?”

The honest answer is: maybe, in mice, for now. That’s not a dismissal. It’s a genuinely interesting result. It’s just not the headline most of the coverage has been running with.

What the Mouse Study Actually Did

Researchers at UC Berkeley, led by Yufan Feng with senior author Danica Chen, took 20-month-old female mice — already elderly by mouse standards — and gave one group semaglutide for three months while a control group got nothing. The treated mice had a median lifespan of 834 days against 742 days for controls. That’s 92 extra days, roughly 12%, on top of an already-old starting point, which matters: this isn’t a drug given from birth, it’s a late-life intervention.

Beyond simply living longer, the treated mice did better on tests of muscle coordination, spatial memory, and blood sugar regulation, and showed lower markers of the low-grade inflammation associated with aging. In several of these measures, semaglutide actually outperformed calorie restriction, the gold-standard intervention researchers have used for decades to extend lifespan in animals.

What it doesn’t tell us: whether the same holds in male mice (only females were studied here), whether starting earlier or continuing longer than three months would help or hurt, and whether any of it translates to a 220-pound human liver instead of a 30-gram mouse one. Mouse-to-human translation in aging research has a long history of not working out, which is exactly why the second study below matters more than the first.

The Human Evidence Is Real, But Narrower Than the Headlines Suggest

A team led by researchers at UC San Diego went back to an existing trial — a 32-week, randomized, double-blind, placebo-controlled Phase 2b study of semaglutide in 84 adults with HIV-associated lipohypertrophy, a condition where fat accumulates abnormally around the abdomen — and ran a new analysis on it, this time looking at epigenetic aging clocks instead of the trial’s original endpoints.

What they found, published in Nature Communications: semaglutide was associated with roughly a 9% slowing on DunedinPACE, a clock that estimates how fast someone is biologically aging month to month, along with supporting signals on GrimAge and clocks tied to inflammation and organ health.

Two things about this are worth sitting with. First, it’s real, peer-reviewed, human, randomized, placebo-controlled evidence — a meaningfully higher bar than most “biohacking” claims ever clear. Second, it’s a post hoc analysis: the trial was designed to study fat redistribution in people with HIV, not aging in general, and the participants aren’t a stand-in for the average person asking about Ozempic. Epigenetic clocks are also, at best, a proxy for aging, not a direct measurement of how long someone will actually live. A slower clock is a genuinely promising signal. It is not the same claim as “you will live longer.”

How This Fits With What We Already Knew

This isn’t the first time GLP-1 drugs have shown effects beyond the scale. The SELECT trial already showed real cardiovascular benefit independent of weight loss, and separate research this year linked semaglutide to a lower risk of depression and a meaningfully lower breast cancer incidence in the studied population. A drug that dampens inflammation and improves metabolic health across several organ systems producing knock-on effects on markers of aging isn’t a wild leap — it’s broadly consistent with everything else this drug class has been doing. That consistency is part of why this result deserves to be taken seriously rather than dismissed as hype. It’s also exactly why it shouldn’t be overstated into something it isn’t yet.

“People ask me constantly whether GLP-1 medicines should be used specifically to slow aging. My answer is the same each time: if you have a real medical reason — obesity, type 2 diabetes, a cardiovascular risk profile these drugs are approved for — this is one more genuinely encouraging data point in an already strong file. If your only reason is ‘I read the drug might slow aging,’ that’s not a prescription-worthy reason on its own, and it won’t be until we have real long-term human outcome data, not a clock reading from a repurposed trial.”

— Dr. Ajit Kumar, MD (Medicine) | MA (Psychology) | Founder, Medimadad

What to Actually Do With This

• Already on a GLP-1 for weight loss, diabetes, or a cardiovascular indication? This is good supporting news, not a reason to change your dose or duration on your own. Keep following your doctor’s plan.
• Considering asking for one purely for anti-aging reasons? Talk to your doctor, but go in with realistic expectations — the evidence for “starts your prescription today” isn’t there yet, and these are real medications with real side effects and costs.
• Watching this space out of curiosity? The number to watch for next is a trial that measures aging as its primary outcome in a general population, not a secondary analysis or a mouse study. That trial doesn’t exist yet.
• Skeptical of the whole GLP-1-does-everything narrative? That instinct isn’t wrong either — extraordinary claims about one drug class solving obesity, heart disease, depression, cancer risk, and now aging deserve real scrutiny, one study at a time, which is exactly what’s happening here.

Frequently Asked Questions

Does this mean Ozempic makes you live longer?

Not proven in humans. The lifespan-extension result is from female mice. The human evidence measures biological aging clocks, which are associated with aging but are not the same as a demonstrated increase in human lifespan.

What is an epigenetic clock, and can it actually predict how long I’ll live?

It’s a lab measurement of chemical changes to your DNA that tend to accumulate with age, used as an estimate of “biological age” versus your calendar age. Clocks like DunedinPACE and GrimAge are validated against real health outcomes in large population studies, but they’re a statistical estimate, not a guarantee for any one person.

Should I ask my doctor for Ozempic just to slow aging?

If you don’t have an approved medical indication (obesity, type 2 diabetes, or an approved cardiovascular risk reason), most doctors wouldn’t prescribe it on anti-aging evidence alone at this stage. That may change as more human data comes in, but it hasn’t yet.

Is this related to the earlier finding that Ozempic helps the heart?

It’s a separate study, but part of the same broader pattern: GLP-1 drugs appear to have effects on inflammation and metabolic health that reach beyond weight loss, which the SELECT cardiovascular trial documented first.

References

1. Feng Y, Chen D, et al. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature. 2026 Sep 2. DOI: 10.1038/s41586-026-10940-7.
2. University of California San Diego-led research team. Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy. Nature Communications. 2026. DOI: 10.1038/s41467-026-72861-3.
3. ClinicalTrials.gov. NCT04019197 — Phase 2b trial of semaglutide in HIV-associated lipohypertrophy.

Related on Medimadad→ What Is Biological Age and How Do You Actually Measure It? | Rapamycin and Longevity: The Most Exciting Anti-Aging Drug Science Has Found | What Does Ozempic Do to Your Heart? The SELECT Trial Explained | Is Metformin the Anti-Aging Drug of the Future?